Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing...
Clinical Trial
Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors
Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site...
Seven Underreported, AI-Infused Healthcare IT Segments Poised for Accelerated Breakout Growth Through 2026
Black Book Research Flash Survey of 126 Healthcare Investors Pinpoints Largely Untapped, High-Conviction Markets for Startups, Scaleups, and Strategic Expansion...
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287,...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive...
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial...
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi®...
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight...
The Untold Truth About President Trump’s Marijuana Rescheduling
The untold truth? Rescheduling may not save the cannabis industry-it could divide it.Past IRS 280E tax liabilities won't vanish-some companies...
Hemogenyx Pharmaceuticals PLC – Third Patient Treated with HG-CT-1 CAR-T Therapy
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort...
Lactéol® diarrhEase™ Launches in the U.S., Bringing Relief for Occasional Diarrhea to Children as Young as Six Months
Clinically studied, drug-free postbiotic now available nationally SHELTON, Conn., Aug. 14, 2025 /PRNewswire/ -- Parents across the U.S. now have...
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the...
HFSA Launches Nation’s First Comprehensive Heart Failure Clinic Database
Built to Connect Patients and Providers, the HFSA Database is Now Open for Searching and Submissions WASHINGTON, Aug. 14, 2025...
IgniteData Raises Series A to Accelerate Global Site Network Expansion and Clinical Trial Data Automation
NEW CASTLE, Del., Aug. 14, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, today announced the close...
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14,...
Hemostemix’s Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell...
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300...
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately...
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Live video webcast on Wednesday, August 20th at 2:40 PM ETOCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its...